WHO ICTRP trial
Phase I/II clinical trial to assess the safety and biological efficacy of…
ACTRN12613000603718 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Recruiting
Key facts
| Trial ID | ACTRN12613000603718 |
|---|---|
| Public title | Phase I/II clinical trial to assess the safety and biological efficacy of treatment with virus-specific, cytotoxic T-lymphocytes from partially matched third-party unrelated donors, in stem cell transplant patients with viral reactivation unresponsive to standard therapy (R3ACT trial) |
| Scientific title | In allogeneic stem cell transplant patients, with viral reactivation unresponsive to standard antiviral therapy, is therapeutic infusion of most closely HLA-matched, third party, donor-derived, virus-specific cytotoxic T-lymphocytes, safe and efficacious? |
| Primary sponsor | Western Sydney Local Health Districit |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase 1 / Phase 2 |
| Countries | Australia;New Zealand |
| Conditions | Viral reactivation post-allogeneic stem cell transplant; Viral reactivation post-allogeneic stem cell transplant;Inflammatory and Immune System - Other inflammatory or immune system disorders;Blood - Haematological diseases;Infection… |
| Interventions | Treatment will consist of an initial infusion of 2 x 10^7/m^2 partially HLA-matched (minimum 1/6), third party, donor-derived, virus-specific (CMV, EBV, and/or adenovirus) cytotoxic T-lymphocytes. Up to 3 subsequent infusions (with an… |
| Registration date | May 28, 2013 |
| Target size | 30 |
| Secondary IDs | Nil known |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: